Cardiovascular. The cardiovascular evaluation consists of a 3-minute step test. It is performed by stepping up and down on a 12-inch bench at 96 beats per minute for 3 minutes. Pulse is counted for one minute immediately following to determine the score. A passing grade is as follows: Acceptable Range all ages 103-119 106-117
Cardiovascular. Targets principally involved in diseases of the heart or of the vascular system, including, without limitation, [**], but excluding Targets of [**]. Oral: Targets principally involved in diseases of the oral cavity, including, without limitation, [**], but excluding Targets of [**].
Cardiovascular. 1. No history or symptomatic form of heart disease or any form requiring therapy.
2. Disturbance of rhyhm. EKG / ECG is performed during initial examination and every five years beginning at age 25 until age 50 and then annually thereafter. Must demonstrate no disturbance of rhythm or other cardiac abnormality on clinical examination, including resting, and when clinically indicated, post-exercise electrocardiograhpy.
3. Must have no increase of heart size beyond normal limits.
Cardiovascular. Irregular heart rhythm from mild to severe.
Cardiovascular. Timing Major Milestones with respect to expected results, achievements, deliverables
Cardiovascular. Includes Xxxx patch products used in cardiovascular and cardiac patching, such as carotid patch, angioplasty, profundaplasty, AV access graft patching, septal defects, outflow tracts, aneurysm repair and other patch angioplasty.
Cardiovascular. Avoid providing the examinee with extraneous clues that will allow him or her to detect the correct answer without actually knowing it. For example, do not put the same key words or descrip- tive words in both the stem and the correct answer but not in the distractors.
Cardiovascular. There have been reports of sudden death in children and adolescents who were taking atomoxetine at usual doses with existing structural cardiac abnormalities. Although some serious structural cardiac abnormalities alone carry an increased risk of sudden death, atomoxetine should only be used with caution in children or adolescents with known serious structural cardiac abnormalities and in consultation with a cardiac specialist. Atomoxetine can affect heart rate and blood pressure. Most patients taking atomoxetine experience a modest increase in heart rate (mean <10 bpm) and/or increase in blood pressure (mean <5 mm Hg) that may not be clinically important. MHRA advice in January 2012 states that atomoxetine causes clinically important increases in blood pressure or heart rate, or both, in a small proportion of patients. Atomoxetine should not be used in patients with severe cardiovascular or cerebrovascular disorders. Thorough pretreatment screening and regular monitoring of cardiovascular status is recommended. Specialist cardiac evaluation and advice should be sought if pretreatment findings suggest cardiac disease or history, or if symptoms suggesting cardiac disease are found during treatment. Atomoxetine can cause prolongation of the QT interval and so should be used with caution in patients with congenital or acquired long QT or a family history of QT prolongation. As orthostatic hypotension has also been reported, atomoxetine should be used with caution in any condition that may predispose patients to hypotension or conditions associated with abrupt heart rate or blood pressure changes.
